Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Randomized Phase 1b/2 Clinical Study to Evaluate TPST-1120 in Combination with the Standard-of-Care First-Line Regimen of Atezolizumab and Bevacizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) not Previously Treated with Systemic Therapy

Next Previous
X
Search
Trial Profile

A Global Randomized Phase 1b/2 Clinical Study to Evaluate TPST-1120 in Combination with the Standard-of-Care First-Line Regimen of Atezolizumab and Bevacizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) not Previously Treated with Systemic Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amezalpat (Primary) ; Atezolizumab; Bevacizumab
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 15 Aug 2024 According to a Tempest Therapeutics media release, the company announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma (HCC).
    • 20 Jun 2024 Positive data from this study presented in a Tempest Therapeutics Media Release.
    • 18 Jun 2024 According to a Tempest Therapeutics media release, company plans to report new data from the global randomized Phase 1b/2 combination study of amezalpat (TPST-1120) with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m. ET.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top